TREATING CANCER WITH EMBRYONIC STEM CELLS: RATIONALE COMES FROM AGING STUDIES

Svetlana V. Ukraintseva and Anatoly I. Yashin

Center for Demographic Studies, Duke University, Durham, NC

TABLE OF CONTENTS

1. Abstract
2. Introduction: Contrast between cancer and aging
3. Opposite manifestation of common signaling pathways in cancer and aging
   3.1. Apoptosis/growth arrest
      3.1.1. P53
      3.1.2. Fas
      3.1.3. Bcl-2
   3.2. The growth signal transduction
      3.2.1. Myc
      3.2.2. Ras
      3.2.3. Tyrosine kinase receptors
4. Application to cancer treatment
5. Concluding remarks
6. Acknowledgements
7. References

1. ABSTRACT

In an earlier poster paper (1) we proposed that cancer can be viewed not only as a fatal disease but also as a local aberrant “rejuvenation” in an organism, and this fact can be useful for developing new anti-aging and anti-cancer treatments. In this paper we provide additional evidence from human and experimental animal studies in support of this view. First, we discuss cancer genes as candidate targets for anti-aging interventions. We review examples in which the life of experimental animals has been prolonged in situations of increased activity of proto-oncogenes - or decreased activity of tumor suppressors - in normal (non-cancerous) cells in vivo. Studies of genetic polymorphisms revealed similar effects on longevity in humans. Second, we discuss the possibility of treating cancer with embryonic stem cells. The grafting of these cells in the tumor environment could be a prospective non-toxic anti-cancer treatment. We discuss recent evidence in support of this view.

2. INTRODUCTION: CONTRAST BETWEEN CANCER AND AGING

In our earlier (poster) paper (1), we suggested that cancer can be viewed not only as a fatal disease but also as a local aberrant “rejuvenation” in an organism. Indeed, a comparison between malignant and aging cells shows that cancer cells do not “age”; their metabolic, proliferative and growth characteristics are the opposite of those observed in cellular aging (both replicative and functional) (2, 3, 4). Cancer cells are potentially immortal (they may avoid apoptosis) and can proliferate to an unlimited extent. Aging cells, both proliferating and post-mitotic, normally die via apoptosis (5, 6, 7). Aging proliferating cells exhibit a decline in proliferative ability with each cell division and finally suffer irreversible growth arrest (also called replicative senescence). It is recognized that cells in a state of irreversible growth arrest (such as mature neurons in vivo or replicatively senescent cells in vitro) are not prone to malignant transformation (e.g., 8, 9, 3). Whereas cancer cells are de-differentiating, the final stage of normal cellular development is terminal differentiation. Cancer cells often have an increased metabolism, while functionally aging cells (e.g., neurons) decline in metabolic activity. Cancer cells may secrete factors that increase blood supply and produce embryonic proteins such as α-fetoprotein, while aging cells do not (2, 3) (Table 1).

Many of these cancer features are inherent to most “young” cells in an organism, that is, embryonic cells. Embryonic cells are capable of extensive proliferation, migration, they secrete factors that increase the local supply of blood, and produce enzymes degrading basal membranes (3) (Table 2).

Thus, cancer and aging are in many instances opposite phenotypic conditions. Recent evidence suggests that these arise from the opposite expression of genes participating in apoptosis/growth arrest and growth signal transduction pathways in cell (such as proto-oncogenes and tumor suppressors). The proto-oncogenes are often suppressed in aging cells, while in cancer cells they are upregulated. Tumor suppressors are permanently expressed in aging cells, while in cancer cells they are downregulated (Table 3). We proposed that controlled “cancer-like” expression of some of these genes may have an anti-aging effect on cells and organisms.
Treating Cancer with Embryo Cells

Table 1. Distinctive features of cancer and aging cells

<table>
<thead>
<tr>
<th>Cancer cells</th>
<th>Aging cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>• potential immortality</td>
<td>• programmed death (apoptosis)</td>
</tr>
<tr>
<td>• unlimited proliferation</td>
<td>• decline in proliferative potential/growth arrest</td>
</tr>
<tr>
<td>• de-differentiation</td>
<td>• terminal differentiation</td>
</tr>
<tr>
<td>• able to migrate</td>
<td>• not able to migrate</td>
</tr>
<tr>
<td>• increased metabolism</td>
<td>• decline in metabolism</td>
</tr>
<tr>
<td>• may secret embryonic proteins</td>
<td>• no embryonic proteins</td>
</tr>
<tr>
<td>• may promote angiogenesis</td>
<td>• do not promote angiogenesis</td>
</tr>
</tbody>
</table>

Sources: 2, 3, 4, 6, 61

Table 2. Common features of cancer and embryonic cells

<table>
<thead>
<tr>
<th>Cancer cells</th>
<th>Embryonic cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>• unlimited proliferative potential</td>
<td>• high/unlimited proliferative potential</td>
</tr>
<tr>
<td>• able to migrate</td>
<td>• able to migrate</td>
</tr>
<tr>
<td>• increased metabolism</td>
<td>• increased metabolism</td>
</tr>
<tr>
<td>• de-differentiated</td>
<td>• undifferentiated</td>
</tr>
<tr>
<td>• able to promote angiogenesis</td>
<td>• able to promote angiogenesis</td>
</tr>
<tr>
<td>• produce embryonic proteins and enzymes degrading basement membranes</td>
<td>• produce embryonic proteins and enzymes degrading basement membranes</td>
</tr>
</tbody>
</table>

Sources: 2, 3, 4, 62

Table 3. Genes oppositely expressed in cancer and aging

<table>
<thead>
<tr>
<th>Gene</th>
<th>Protein function</th>
<th>In cancer cells</th>
<th>In aging cells</th>
<th>In aging organisms</th>
</tr>
</thead>
<tbody>
<tr>
<td>p53</td>
<td>Induces cellular apoptosis/growth arrest; tumor suppressor</td>
<td>Downregulated in most human cancers (14, 6)</td>
<td>Elevated expression (17, 18)</td>
<td>Upregulating mutation is associated with early aging phenotype and lower cancer risk in mice (19, 20)</td>
</tr>
<tr>
<td>fas (CD95)</td>
<td>“Death” receptor of apoptotic signal</td>
<td>Decreased expression (27)</td>
<td>Higher expression on lymphocytes from adults compared with newborns (30)</td>
<td>Proportion of cells expressing CD95 is higher in older individuals (29)</td>
</tr>
<tr>
<td>bcl-2</td>
<td>Anti-apoptotic protein; proto-oncogen</td>
<td>Overexpressed in some cancers (31)</td>
<td>Decreased levels (63, 32)</td>
<td>Decreased expression in lymphocytes from older individuals (29)</td>
</tr>
</tbody>
</table>

Growth signal transduction

<table>
<thead>
<tr>
<th>Gene</th>
<th>Function</th>
<th>In cancer cells</th>
<th>In aging cells</th>
<th>In aging organisms</th>
</tr>
</thead>
<tbody>
<tr>
<td>myc</td>
<td>Transcription factor; proto-oncogen</td>
<td>Overexpressed in many cancers (32)</td>
<td>Expression is lower in senescent cells (35, 32). Sustained expression rescues embryo cells from senescence (34).</td>
<td>Aging diminishes the myc expression including that in response to stress (66)</td>
</tr>
<tr>
<td>ras</td>
<td>Signal transducer; proto-oncogen</td>
<td>Activated in some cancers (36)</td>
<td>Decreased expression in senescent cells (38)</td>
<td>Activity is lower in old rats (37). Controlled expression extends the reproductive life span in yeast (39)</td>
</tr>
<tr>
<td>tyrosine kinase receptors</td>
<td>Growth factor receptors (e.g. erb-B, TRK); proto-oncogenes</td>
<td>Overexpressed in some cancers (32)</td>
<td>Receptor density and mitogenic response decrease with donor age (41, 42)</td>
<td>Overexpression of tkr-1 increases longevity in nematodes (44)</td>
</tr>
</tbody>
</table>

3. OPPOSITE MANIFESTATION OF COMMON SIGNALING PATHWAYS IN CANCER AND AGING

3.1. Apoptosis/growth arrest

3.1.1. P53

The potential immortality of cancer cells results from their ability to avoid apoptosis. The unlimited growth and proliferation of cancer cells are linked to their ability to avoid irreversible growth arrest (2, 4). Both these qualities require the suppression of p53 tumor suppressor gene (6, 10, 11). The latter codes a transcription factor that induces apoptosis or cell circle arrest at the G1-S phase. It may also promote cell differentiation. P53 protein influences expression of many target genes, such as fas, bax, bcl-2, and p21 (12, 13) (Figure 1)
Treating Cancer with Embryo Cells

Figure 1. Selected genetic targets of P53 (Sources: 15, 28, 64).

Figure 2. Simplified picture of two major apoptotic pathways: via “Death” receptor (Fas), and via mitochondrion (Sources: 15, 28, 65).

P53 is a key tumour suppressor. Mutations that downregulate or completely knock out this gene are found in all major histogenetic groups of cancer, such as colon (~60% cases), lung (~70% cases), brain (~40% cases), and esophagus (~60% cases) cancers. It is estimated that p53 mutations are the most frequent genetic event in human cancer cells (14). Even if p53 is not mutated, it is still downregulated in most human cancers (11, 15).

As for aging, p53 is permanently expressed in senescent cells (9, 10, 16). P53 gene expression increased significantly in aged rat brain (17). Elevated P53 protein is found to be associated with aging in human diploid fibroblasts (18). Mice carrying the p53 mutation with a phenotypic effect analogous to the upregulation of this gene display an early aging phenotype along with a lower risk of cancer development (19, 20). Long-living mutant mice, p66shc−/−, have shown an impaired p53 apoptotic response (21). Introducing the null p53 allele has protected Ku80−/− and mTR−/− mice from premature aging (22, 23), indicating that the senescence phenotypes were p53-dependent (24). Recently, Van Heemst (2003) demonstrated that individuals with the Pro/Pro genotype of p53 (corresponding to reduced apoptosis in cell) significantly increased both survival rates and the proportion of deaths from cancer at oldest old ages (85+) (25).

Thus, it follows that the upregulation of the p53 tumor suppressor gene is required for both cellular and organismic aging, while its downregulation may have an anti-aging effect on cells and (at least in some cases) on organisms (Table 3).

3.1.2. Fas

One apoptotic pathway involves the transduction of a signal from outside Fas-ligand (FasL) to the “death” receptor, CD95 (or Fas), on the cellular membrane. This signal activates a cascade of caspases, which are intracellular enzymes destroying cell proteins (Figure 2).

The expression of CD95 is weaker on cancer cells. Cancer cells may avoid apoptosis when, for instance, Fas receptor is in soluble form (26) or when its expression to cell surface is decreased (27). This, together with increased expression of FasL, may help cancer cells to avoid immune surveillance because FasL is able to counterattack host lymphocytes. The decreased expression of CD95 in cancer cells can be directly related to downregulation of p53 because the latter has the ability to induce transport of CD95 from the golgi apparatus to the cell surface (28).

As regards aging, the susceptibility of cells to Fas-mediated apoptosis was shown to increase with the age of the donor (29). The proportion of CD4+ and CD8+ lymphocytes expressing the Fas receptor was significantly higher in serum taken from old compared to that from young individuals (45% vs. 29%). It was possible to induce an in vitro apoptosis in 55% of the CD4+ cells of old (65-95) donors, while it was possible in only 26% of the cells of young (20-29) donors. A similar relationship was observed for CD8+ cells (29). Other studies show that the Fas receptor is weakly expressed on the lymphocytes of newborns; however, its expression progressively increases in adulthood (30).

3.1.3. Bcl-2

Another apoptotic pathway involves the release of Cytochrome C from mitochondria and following activation of effector caspases. The Bcl-2 protein blocks this apoptotic activity of mitochondria (see Figure 2). The bcl-2 is known as a proto-oncogen overexpressed in some cancers (31). As for aging, the density of this protein is
Treating Cancer with Embryo Cells

3.2. The Growth Signal Transduction

The proliferation, the growth signal autonomy and the de-differentiation of cancer cells are all associated with the upregulation of the growth signal transduction pathway. This typical pathway involves the transmission of a signal from an external growth factor to the growth factor receptor on a cellular membrane (such as tyrosine kinase receptor), and from there to cytoplasmic proteins (e.g., GSP and RAS), passing the signal to a nucleus transcription factor such as myc (Figure 3). Myc has the ability to induce cell division and suppress cell differentiation (32, 33).

The majority of known proto-oncogenes normally participate in the growth signal transduction pathway in cells (31). Among these, ras, myc and tyrosine kinase receptors are particularly involved in both aging and cancer.

3.2.1. Myc

Elevated myc transcription is found in many human cancers (32, 33). However, it is expressed at much higher levels - not only in cancer, but also in normal young proliferating cells - when compared to terminally differentiated non-dividing ones (32). The sustained expression of the myc rescued rat embryo cells from senescence (34). At the same time, significantly decreased levels of c-myc transcription have been found in late passage human fibroblasts compared to early passage cells (35).

3.2.2. Ras

Ras is a proto-oncogen activated in many cancers (36). As for aging, Ras activity has been found to be lower in cells isolated from old rats compared to those from young ones (37). Ras expression decreased during in vitro senescence of human fibroblasts (38). At the same time, the controlled overexpression of the v-Ha-ras has extended reproductive life span in yeast nearly two-fold (39).

3.2.3. Tyrosine kinase receptors

Expression of these receptors is elevated in some human cancers (32, 31, 40). As for aging, human fibroblasts express fewer epidermal growth factor receptors and display a weaker mitogenic response to the growth factor with increasing donor age (41, 42, 43). It has been demonstrated that upregulation of a tyrosine kinase receptor may increase both longevity and stress resistance in nematodes. The overexpression of tkr-1 has significantly improved their survival (average 65%) and resistance to heat and ultraviolet irradiation (44).

Thus, there is strong evidence that proto-oncogenes participating in growth signal transduction pathway are oppositely expressed in cancer and aging cells. There is also limited evidence that controlled activation of some of these proto-oncogenes may have an anti-aging effect on cells and organisms (Table 3).

One should notice that growth signal transduction pathway has been intensively studied last years in relation to aging (45, 46). This pathway has been proposed to be a conserved regulator of aging in different species (see e.g., 47, 48, 49, 50). Mutations of many relevant genes (e.g., daf-2 and age-1 in C. elegans) have been found to increase longevity in experimental animals (51, 52, 53, 54). However, only few such mutations manifested themselves in the activation or overexpression of a known proto-oncogene (44). Thus, additional studies are needed to explore the effect of the controlled “cancer-like” upregulation of proto-oncogenes involved in growth signalling pathways on aging and longevity.

4. APPLICATION TO ANTI-CANCER TREATMENT

The fact that cancer cells do not “age” suggests that these cells have high competitive ability in environment of aging host cells. The proportion of aging cells increases with age, and proliferative and survival advantage of cancer cells increases in an old organism, too, in part providing an increase in cancer risk with age (55). In this situation, “rejuvenation” of normal host cells surrounding the tumor could be a prospective anti-cancer treatment. One such method may involve grafting young proliferating cells (e.g., embryonic stem cells) in the area near a malignant tumor. Such therapy would help to supplant cancer cells, rather than to kill them.

There are data - although limited - supporting this
Treating Cancer with Embryo Cells

view. Neural stem cells (NSC) have shown a potential to hunt malignant cells (when implanted into intracranial gliomas in adult rodents in vivo). NSC surrounded the tumor and expanded aggressively advancing tumor cells (56). Yip et al., (2003) suggested using this property of NSC for targeted drug delivery during cancer treatment (57). Earlier, Barnea et al., (1996) found that fractions derived from human embryonal neural tissue extracts significantly suppress the proliferation of human breast cancer cells. Significant inhibition of proliferation of osteosarcoma and fibrosarcoma was also obtained (58). Joshi et al., (2000) revealed significant increase in the survival of leukemia as well as breast cancer bearing mice that received in vitro IL-2-activated peripheral blood stem cells after tumor transplantation compared with untreated mice (59).

After this manuscript had already been written, additional evidence on the possibility of supplanting malignant cells with normal young proliferating cells came to light. During the recent 2nd Congress of the International Society of Stem Cell Research (ISSCR), Staffin et al., (2004) demonstrated that neural progenitor cells can inhibit malignant glioma growth in vivo (60). Glioma cells were co-inoculated with neural progenitor cells (embryonic as well as adult) into a rat’s CNS. Embryonic (but not adult) neural progenitor cells inhibited glioma cell division and induced glioma cell apoptosis. Complete tumor remission occurred about 20% of the animals. The importance of this study is that authors have compared outcomes of treatments with adult versus embryonic progenitor cells and have proved that only embryonic (i.e., the youngest) cells have an effect on these tumors.

5. CONCLUDING REMARKS

Comparative analysis shows that phenotypes of cancer and aging are, in many instances, opposite. Cancer cells do not “age”; their metabolic and growth characteristics are opposite to those observed in cellular aging (both replicative and functional). That is, cancer manifests itself as local uncontrolled “rejuvenation” in an organism (1).

Available data indicate that the opposite phenotypic features of aging and cancer results from the opposite manifestation of common genes participating in apoptosis/growth arrest or growth signal transduction pathways. Genes normally managing cellular aging promote cancer when contrarily expressed.

Understanding the opposition between cancer and aging has practical application to developing new anti-aging and anti-cancer interventions. The controlled overexpression of proto-oncogenes as well as the downregulation of tumor suppressors might produce an anti-aging effect in cells and organisms. This, however, needs further and careful investigation in life-term experiments. Application to cancer therapy seems more realistic for today. Rejuvenation of normal host cells surrounding the tumor could be a prospective anti-cancer treatment. One such method may involve grafting young proliferating cells (e.g., embryonic stem cells) in the area near a malignant tumor.

6. ACKNOWLEDGEMENTS

The authors wish to thank Prof. James W. Vaupel for the opportunity to conduct part of this work at the Max Planck Institute for Demographic Research, Germany, and for his valuable comments. We are thankful to Leatta Welch for help in preparing this manuscript. The following federal grant supported this paper: 5P01-AG-17937-05, Population Models of Factors Affecting Health Trends; and 5 U01-AG07198-17.

7. REFERENCES

Treatting Cancer with Embryo Cells

Jan 187, 1, 112-26 (1999)


Treating Cancer with Embryo Cells

(1986)


66. Shida M, Isoyama S. Effects of age on c-fos and c-myc gene expression in response to hemodynamic stress in isolated, perfused rat hearts. *J Mol Cell Cardiol.* 25(9),
Treating Cancer with Embryo Cells

1025-35 (1993)

Key Words: Cancer, Aging, Apoptosis, Growth arrest, Signal transduction, Oncogenes, Tumor suppressors, Review

Send correspondence to: Svetlana V. Ukraintseva, Ph.D., Duke University, Center for Demographic Studies, 2117 Campus Drive, Box 90408, Durham, NC, 27708-0408, USA, Tel: 919-682-9759 ext 224, Fax: 919-956-9963, E-mail: ukraintseva@cds.duke.edu